Method for the management of hyperplasia

Claim 1

A method for administering an estrogenic composition for estrogen replacement in a woman exhibiting a decrease in estrogen secretion, and for administering a progestational composition for the management of endometrial hyperplasia in said woman, which method comprises: (a) placing in the vagina of said woman a vaginal dispenser adapted and shaped for easy placement and comfortable retention in the vagina, the dispenser comprising: (1) a multiplicity of tubes with each tube comprising a wall that surrounds an internal space, said wall comprising a member selected from the group consisting of olefin, vinyl, condensation, addition and rubber diffusion and microporous polymers; (2) a composition in the internal space, said composition comprising about 2 mcg to 7.5 g of an estrogenic steroid, pharmaceutically acceptable mass transfer carrier for said steroids; (b) administering the estrogenic steroid through the wall from the dispenser into the vagina in a therapeutically effective amount for replacing the estrogen in said woman; and, (c) administering the progestational steroid through the wall in a therapeutically effective amount from the dispenser for substantially lessening endometrial hyperplasia in said woman.

Claim 2

A method for administering an estrogenic composition for estrogen replacement in a woman exhibiting a decrease in estrogen secretion, and for administering a progestational composition for the management of endometrial hyperplasia in said woman, which method comprises: (a) placing in the vagina of said woman a vaginal dispenser adapted and shaped for easy placement and comfortable retention in the vagina, the dispenser comprising: (1) a multiplicity of tubes with each tube comprising a wall that surrounds an internal space, said wall comprising a member selected from the group consisting of olefin, vinyl, condensation, addition and rubber diffusion and microporous polymers; (2) a composition in the internal space, said composition comprising about 2 mcg to 7.5 g of an estrogenic steroid, pharmaceutically acceptable mass transfer carrier for said steroids; (b) administering the estrogenic steroid through the wall from the dispenser into the vagina in a therapeutically effective amount for replacing the estrogen in said woman; and, (c) administering the progestational steroid through the wall in a therapeutically effective amount from the dispenser for substantially lessening endometrial hyperplasia in said woman.

Claim 3

A method of estrogen replacement for a woman in need of estrogen replacement, and for progestin management of endometrium hyperplasia responsive to a progestin in said woman, which method comprises: (a) placing in the vagina of said woman a dispenser comprising: (2) at least one tube comprising a wall composition that surrounds an internal lumen, said wall composition vinyl, condensation, and addition polymer that releases a steroid by passage through micropores in the wall, which micropores are formed by leaching a pore former from the wall, said dispenser adapted and shaped for easy placement and comfortable retention in the vagina; (2) a pharmaeutically acceptable carrier in the lumen, said carrier comprising a member selected from the group consisting of solid, liquid and semi-liquid carriers and comprising up to 7.5 g of dissolved and undissolved estrogen and progestin steroids; (b) administering the estrogen steroid from the dispenser through micropores in the wall into the vagina in a therapeutically effective amount for at least five days for replacing estrogen in said woman; and, (c) administering the progestin steroid from the dispenser through micropores in the wall into the vagina in endometrium hyperplasia in said woman.

Claim 4

A method of estrogen replacement for a woman in need of estrogen replacement, and for progestin management of endometrium hyperplasia responsive to a progestin in said woman, which method comprises: (a) placing in the vagina of said woman a dispenser comprising: (2) at least one tube comprising a wall composition that surrounds an internal lumen, said wall composition vinyl, condensation, and addition polymer that releases a steroid by passage through micropores in the wall, which micropores are formed by leaching a pore former from the wall, said dispenser adapted and shaped for easy placement and comfortable retention in the vagina; (2) a pharmaeutically acceptable carrier in the lumen, said carrier comprising a member selected from the group consisting of solid, liquid and semi-liquid carriers and comprising up to 7.5 g of dissolved and undissolved estrogen and progestin steroids; (b) administering the estrogen steroid from the dispenser through micropores in the wall into the vagina in a therapeutically effective amount for at least five days for replacing estrogen in said woman; and, (c) administering the progestin steroid from the dispenser through micropores in the wall into the vagina in endometrium hyperplasia in said woman.